Carl Zeiss Meditec AG
ISIN: DE0005313704 | Ticker: AFX | LEI: 529900GRL4MZ8NMOOK95
Under the umbrella of the MDAX and TecDAX-listed company Carl Zeiss Meditec AG, which is one of the world’s leading medical technology companies, the Medical Technology activities of ZEISS are bundled. Carl Zeiss AG holds ca. 59 percent interest.
The Carl Zeiss Meditec AG has set itself the task to develop innovative products to improve the diagnosis and treatment of diseases. The solutions the Company develops aim to simplify clinical workflows and allow physicians to focus all their attention on their work and their patients. After all, at the end we want the patient to leave the clinic with the best possible outcome and a high level of satisfaction.
Therefor we are guided by our Mission to uniquely enable healthcare professionals worldwide to improve the lives of their patients in ophthalmology, microsurgery and other medical growth sectors and advance the standards of care with our proven medical technology and application competence.
1977
Served areaWorldwide
Headcount3,531
HeadquartersGöschwitzer Straße 51-52, 7745 Jena – Germany
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | ENG | ENG | ENG | |
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | GER ENG | GER ENG | ENG GER | ENG |
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | GER ENG | GER ENG | ENG GER | ENG GER |
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | GER ENG | GER ENG | GER ENG | GER ENG |
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | GER ENG | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | ENG | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
89,440,570
IPOMarch 20, 2000
Stock exchange(s)Frankfurt Stock Exchange